Site icon Market Globalist

Infinity Pharmaceuticals Inc. (INFI) stock gains during pre-market. Let’s see why?

RACE Stock

RACE Stock

Infinity Pharmaceuticals Inc. (INFI) stock declined by 31.53% at the last close whereas the INFI stock price surges by 49.34% in the pre-market trading session. Infinity is a medical biotechnology firm working on eganelisib (IPI-549) which is an oral immuno-oncology macrophage reprogramming therapy that has been shown to target a basic biologic process of immune suppression in cancer in numerous clinical trials.

What’s the update on INFI stock?

Financial Results

Infinity Pharmaceuticals released a company update as well as financial data for the second quarter of 2021.


Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '22.
Small-cap Uranium stocks are booming in 2022! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here. .

Sponsored


What else?

Infinity Pharmaceuticals has released new data on MARIO-275. MARIO-275 is a Phase 2 trial that is randomized and placebo-controlled. The goal of the research is to see how effective and safe eganelisib in conjunction with nivolumab (Opdivo) is in platinum-resistant cancer patients. In addition, data was also used in I/O naive individuals with advanced UC. However the data from MARIO-3,  which  is an ongoing Phase 2 trial in patients with unresectable locally advanced or metastatic TNBC that is testing eganelisib in a new triple combination in the front-line scenario with atezolizumab (Tecentriq) and nab-paclitaxel (Abraxane).

Exit mobile version